Dendreon Corporation Launches New Corporate Website.Business Editors & Health/Medical Writers BIOWIRE2K SEATTLE--(BW HealthWire)--July 11, 2001 Dendreon Corporation (Nasdaq:DNDN) today announced the launch of its redesigned corporate website: www.dendreon.com. The new site offers expanded information on the company's immunotherapeutic technologies and clinical programs, including current Phase III trials for Provenge(TM), Dendreon's therapeutic vaccine therapeutic vaccine Immunology A vaccine–eg, Salk's Remune™ intended to treat a viral infection by stimulating the immune system. See Vaccine therapy. for men with advanced and earlier stage prostate cancer prostate cancer, cancer originating in the prostate gland. Prostate cancer is the leading malignancy in men in the United States and is second only to lung cancer as a cause of cancer death in men. . The website also features an animated description of the Company's technology approach (www.dendreon.com/technology/den_vaccine_approach.html) that builds upon the natural capabilities of dendritic cells to stimulate the immune system immune system Cells, cell products, organs, and structures of the body involved in the detection and destruction of foreign invaders, such as bacteria, viruses, and cancer cells. Immunity is based on the system's ability to launch a defense against such invaders. to attack and kill cancer cells. A pop-up glossary is also available throughout the site to aid visitors. Dendreon Corporation (www.dendreon.com) is dedicated to the discovery and development of novel products for the treatment of cancer through its innovative manipulation of the immune system. In addition to Provenge, Dendreon has two therapeutic vaccines in clinical trials -- Mylovenge(TM), for the treatment of multiple myeloma multiple myeloma A malignant proliferation of abnormal plasma cells that populate the marrow-containing bones of the body. The affected plasma cells produce myeloma protein, a monoclonal antibody that replaces normal antibodies in the blood, thereby increasing susceptibility , in Phase II trials; and APC (1) (American Power Conversion Corporation, West Kingston, RI, www.apcc.com) The leading manufacturer of UPS systems and surge suppressors, founded in 1981 by Rodger Dowdell, Neil Rasmussen and Emanual Landsman, three electronic power engineers who had worked at MIT. 8024, for the treatment of breast, ovarian and colon cancers, in Phase I trials. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion